AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
hATTR Polyneuropathy in Russia
Completed
- Conditions
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT06365593
- Locations
- 🇷🇺
Research Site, Saint-Petersburg, Russian Federation
Real-World Treatment Study of Koselugo (Selumetinib)
Recruiting
- Conditions
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT06360406
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 675
- Registration Number
- NCT06357533
- Locations
- 🇬🇧
Research Site, Truro, United Kingdom
A Study to Investigate the Pharmacokinetics of Baxdrostat When Given Alone and in Combination With Itraconazole in Healthy Participants
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT06357520
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 55000
- Registration Number
- NCT06355934
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT06350123
- Locations
- 🇻🇳
Research Site, Hochiminh city, Vietnam
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 582
- Registration Number
- NCT06350097
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
A Positron-emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy Volunteers
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 7
- Registration Number
- NCT06348355
- Locations
- 🇸🇪
Research Site, Solna, Sweden
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 589
- Registration Number
- NCT06346392
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT06344104
- Locations
- 🇻🇳
Research Site, Hochiminh, Vietnam
© Copyright 2024. All Rights Reserved by MedPath